Keros Therapeutics (KROS) Competitor Comparison
We are evaluating the key criteria listed to compare Keros Therapeutics (KROS) against its competitors in the Biotechnology industry.
Market Capitalization
70 / 368Gross Profits
232 / 278Total Revenue
286 / 300EBITDA
253 / 337Free Cashflow
263 / 352Quick Ratio
37 / 357Earnings per Share
304 / 359Dividend yield
0 / 6Total Cash
117 / 358Performance 3 years
197 / 368Performance 5 years
136 / 368Performance 10 years
114 / 368Linearity 3 years
111 / 368Linearity 5 years
28 / 368Linearity 10 years
20 / 367Total Rank
175 / 368Dividend Rank
181 / 368Valuation Rank
276 / 368Piotroski Rank
233 / 368Muliplier Rank
134 / 368Market Capitalization - KROS ranking 70 / 368
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.